IRIS-BioFreedom Cohort in the IRIS-DES Registry
Launched by SEUNG-JUNG PARK · Jun 15, 2017
Trial Information
Current as of July 22, 2025
Recruiting
Keywords
ClinConnect Summary
The IRIS-BioFreedom study is looking at how effective and safe the BIOFREEDOM™ FAMILY stent is for treating coronary stenosis, which is a narrowing of the arteries that supply blood to the heart. Researchers want to see how this stent performs in real-world situations compared to other similar devices. The trial is currently recruiting participants who are 19 years or older and have received a BIOFREEDOM™ FAMILY stent.
If you join this study, you'll help researchers understand how well this stent works for patients like you. It's important to note that if you have had both the BIOFREEDOM™ FAMILY stent and another type of stent placed at the same time, or if you have serious heart conditions like cardiac shock or a life expectancy of less than a year, you wouldn't be eligible. Participating in this trial could contribute to improving heart care for many people in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age 19 and more
- • Patient with BIOFREEDOM™ FAMILY stent
- • Written consent
- Exclusion Criteria:
- • Intervention with BIOFREEDOM™ FAMILY stent and other drug eluting stent at the same time
- • Life-expectancy less than 1 year
- • Cardiac shock
About Seung Jung Park
Seung-Jung Park is a distinguished clinical trial sponsor recognized for his commitment to advancing medical research and innovation. With a focus on cardiology and interventional procedures, he leads initiatives that aim to improve patient outcomes through rigorous clinical trials. His expertise in trial design and execution ensures adherence to the highest ethical standards and regulatory requirements. By fostering collaboration among multidisciplinary teams, Seung-Jung Park drives the development of cutting-edge therapies, contributing significantly to the scientific community and enhancing the landscape of modern medicine.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Seoul, , Korea, Republic Of
Daegu, , Korea, Republic Of
Daejeon, , Korea, Republic Of
Pusan, , Korea, Republic Of
Daegu, , Korea, Republic Of
Gwangju, , Korea, Republic Of
Seoul, , Korea, Republic Of
Seoul, , Korea, Republic Of
Cheonan, , Korea, Republic Of
Ilsan, , Korea, Republic Of
Anyang, , Korea, Republic Of
Chuncheon, , Korea, Republic Of
Incheon, , Korea, Republic Of
Yangsan, , Korea, Republic Of
Seongnam, , Korea, Republic Of
Daejeon, , Korea, Republic Of
Seoul, , Korea, Republic Of
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials